Location History:
- Hanover, DE (1998)
- Hannover, DE (2000 - 2012)
Company Filing History:
3 out of 5 
2 out of 6 
1 out of 1,164 
Years Active: 1998-2012
Title: The Innovative Contributions of Knut Adermann
Introduction
Knut Adermann, an accomplished inventor based in Hannover, Germany, has made significant strides in the field of medical biotechnology. With a portfolio that boasts seven patents, his work primarily focuses on the development of peptides for the treatment and diagnosis of viral diseases, particularly HIV.
Latest Patents
Adermann's latest innovations feature groundbreaking patents including a "Human semen enhancer of viral infection peptides (SEVI)" which pertains to specific peptides derived from a segment of human prostatic acid phosphatase. This invention underscores the potential use of these peptides in medicaments and diagnostics related to viral infections. Another notable patent concerns "Peptides and their use for the treatment of HIV infections," which involves a complex structure of amino acids designed to exhibit biological activity against viral infections. This invention highlights the intricate relationships between peptide sequences and their therapeutic applications.
Career Highlights
Throughout his career, Knut Adermann has collaborated with notable companies such as Haemopep Pharma GmbH and Ipf Pharmaceuticals GmbH. His extensive work in these organizations showcases his commitment to advancing medical research and developing innovative treatment options that bridge the gap between science and clinical application.
Collaborations
Adermann has partnered with esteemed colleagues in his field, including Wolf-Georg Forssmann and Jan Münch. These collaborations have facilitated the exchange of ideas and bolstered the development of innovative solutions in biotechnology, particularly in relation to viral diseases.
Conclusion
In conclusion, Knut Adermann’s contributions to the field of medical biotechnology are commendable, reflecting his dedication to enhancing healthcare through innovative peptide research. With his array of patents and meaningful collaborations, Adermann continues to pave the way for future developments in the treatment and diagnosis of viral infections.